Overview


Carbinoxamine acts as an antihistamine, and anticholinergic Agent. It can be used to treat hay fever and mild Urticaria. Carbinoxamine, a histamine antagonist and specifically an H1-antagonist, is used. The rotoxamine prescription drug is made from the maleic acid salt. In various nations across the world, consumers can buy carboxyxamine either alone or in combination with pseudoephedrine and other decongestants like paracetamol and codeine. The FDA asked that they be taken out of circulation because carbinoxamine was being sold illegally. Twenty-one documented deaths of toddlers under the age of two who had been given carbinoxamine-containing goods led to this action. Despite the fact that this medication hasn't been tested on infants and toddlers, OTC goods containing it are nevertheless being marketed to them. All formulations containing carbinoxamine are now only permitted for use in grownups or kids who are at least three years old. To relieve symptoms of seasonal and persistent allergic rhinitis as well as vasomotor and vasomotor conjunctivitis due to foods and inhaled allergens.

For the treatment of minor, uncomplicated allergic skin manifestations such as urticaria or angioedema, and for allergic reactions to plasma or blood. The drug is also used to treat irritant cough, nausea, vomiting, vertigo, and motion sickness symptoms. It is also used to treat drug-induced extrapyramidal reactions and mild Parkinson's disease. Carbinoxamine does not prevent the release of histamine like cromolyn or nedocromil. Instead, it competes with free histamine to bind at HA receptor sites. Carbinoxamine competely blocks the effects of histamine in the GI tract and uterus on HA receptors. Ethanolamine derivatives are more anticholinergic than other antihistamines. This may explain the antidyskinetic effect of carbinoxamine. Carbinoxamine competes against free histamine in binding to HA-receptor sites. This blocks the histamine HA receptor binding effects, resulting in a decrease of negative side effects. Carbinoxamine appears to have an anticholinergic effect due to a central antimuscarinic action, which may also be responsible for its antiemetic properties. However, the exact mechanism remains unknown.

Because many unapproved preparations containing carbinoxamine contained inappropriate labelling that promoted unapproved uses (including the management of congestion, cough, the common cold, and the use in children under 2 years of age), which could potentially result in serious health risks, the product label for carbinoxamine as an over-the-counter cough and cold medicine is being modified to state "do not use" in children under 4 years of age in order to prevent and reduce misuse. Due to elements such as the rising prevalence of allergies, allergic responses, and increased exposure to the outside environment, the carbinoxamine market is anticipated to expand over the forecast period. Environment Drug companies' near-term R D efforts are also anticipated to boost market growth. This has some unintended consequences.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Carbinoxamine Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Carbinoxamine Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  •  Abbott
  •  Johnson and Johnson
  •  Endo Pharma
  •  Cipla Ltd
  •  CosMed Pharmaceuticals
  •  Perrigo
  •  Mikart Pharmaceuticals
  •  October Pharma
  •  Stanley Pharma
  •  Medical Union Pharmaceuticals

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product

  •  Tablet
  •  Oral

By Application

  •  Hospitals
  •  Drug Stores
  •  Others

By Region

  •  North America
  •  Europe
  •  Asia-Pacific
  •  Latin America
  •  Middle East and Africa

  •  Tier 1 players- established companies in the market with a major market share
  •  Tier 2 players
  •  Emerging players which are growing rapidly
  •  New Entrants

  •  Growth prospects
  •  SWOT analysis
  •  Key trends
  •  Key data-points affecting market growth

  •  To provide with an exhaustive analysis on the Carbinoxamine Market By Product, By Application and By Region.
  •  To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  •  To evaluate and forecast micro-markets and the overall market
  •  To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  •  To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  •  We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  •  The customization Mobility Care offered are free of charge with purchase of any license of the report
  •  You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Carbinoxamine Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Carbinoxamine Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Carbinoxamine Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Carbinoxamine Market, By Product Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Tablet
        2. Oral

  • 8.   Carbinoxamine Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Drug Stores
        3. Others

  • 9.   North America Carbinoxamine Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Carbinoxamine Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Carbinoxamine Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Carbinoxamine Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Carbinoxamine Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Abbott
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Johnson and Johnson
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Endo Pharma
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Cipla Ltd
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. CosMed Pharmaceuticals
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Perrigo
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Mikart Pharmaceuticals
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. October Pharma
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Stanley Pharma
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
          10. Medical Union Pharmaceuticals
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients